adam9 binding molecule, pharmaceutical composition, use of the adam9 binding molecule and method for treating a disease or condition associated with or characterized by the expression of adam9 in an individual
BHASWATI BARAT,DERYK T. LOO,EZIO BONVINI,GUNDO DIEDRICH,JUNIPER A. SCRIBNER,LESLIE S. JOHNSON
申请号：
BR112019012950
公开号：
BR112019012950A2
申请日:
2017.12.21
申请国别(地区):
BR
年份:
2019
代理人:
摘要：
adam9-binding molecule, pharmaceutical composition, use of the adam9-binding molecule and method for treating a disease or condition associated with or characterized by the expression of adam9 in an individual The present invention is directed to molecules such as monospecific antibodies and bi-binding molecules. , tri or multispecific, including diabodies, bites, and antibodies that are capable of specifically binding to "disintegrin domain-containing metalloproteinase 9 protein" ("adam9"). The invention particularly relates to such binding molecules which are capable of displaying high affinity binding to human and non-human adam. The invention further particularly relates to such molecules which are therefore cross-reactive to human adam9 and adam9 from a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to all such adam9-binding molecules which comprise a light chain variable domain (v1) and / or a heavy chain variable domain (vh) that has been humanized and / or deimmunized, so as to exhibit reduced immunogenicity upon administering such an adam9 binding molecule to a recipient subject. The invention is also directed to pharmaceutical compositions containing any of these adam9-binding molecules, and to methods involving the use of any of these adam9-binding molecules in the treatment of cancer and other diseases and conditions.molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo a presente invenção é direcionada a moléculas, como anticorpos monoespecíficos e moléculas de ligação bi, tri ou multiespecíficas, incluindo diacorpos, bites, e anticorpos que sejam capazes de ligação de maneira específica a “proteína contendo domínio de desintegrina e metaloproteinase 9” (“adam9”). a invenção particularmente se refere a essas moléculas de ligação que são capazes de apresentar ligação de alta
